Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy

BACKGROUND: Outpatients treated with oral anti-cancer drugs, including selective cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), may benefit from a pharmacy practice setting adapted to support proper oral anti-cancer drug monitoring. This real-world study aimed to characterize patient-centered pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Marineau, Alexandre, St-Pierre, Catherine, Lessard-Hurtubise, Roxanne, David, Marie-Ève, Adam, Jean-Philippe, Chabot, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302375/
https://www.ncbi.nlm.nih.gov/pubmed/35642282
http://dx.doi.org/10.1177/10781552221102884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302375/
https://www.ncbi.nlm.nih.gov/pubmed/35642282
http://dx.doi.org/10.1177/10781552221102884

Ejemplares similares